Arkin Capital Closes on $100m for Bio Ventures III – A New Wave in…

Team S · 2026-01-16T13:30:04.000Z

Arkin Capital has successfully closed its latest venture fund, Arkin Bio Ventures III , securing $100 million to accelerate investments in biotechnology companies at the pre-clinical and early clinical stages of development. The announcement positions the Israel-based investment firm as a continued leader in life sciences venture capital, focusing on high-impact therapeutic areas such as oncology, immunology, inflammation, and rare diseases. This funding round includes participation from prominent institutional investors backing Arkin Bio Ventures III. Key supporters comprise Phoenix Insurance , Clal Insurance , and Amitim Pension Funds alongside a significant commitment from Arkin Capital itself. Arkin plans to deploy this capital across 10–12 companies globally , leveraging deep scientific expertise and a targeted investment strategy that aims to help startups reach critical clinical proof-of-concept milestones. Led by Managing Partner Pini Orbach , Arkin Capital will continue its biology-first approach blending rigorous scientific diligence with hands-on development support to guide early biotech companies toward significant value inflection points. The new fund builds on the firm’s biotech investment history, following the launches of Arkin Bio Ventures I (2016) and II (2020), and highlights a broader trend of renewed investor confidence in life sciences. #Biotech #VentureCapital #LifeSciences #EarlyStageFunding #HealthcareInnovation #InvestmentNews #ArkinCapital

Member Login Get Access

Arkin Capital Closes on $100m for Bio Ventures III – A New Wave in… | Newnex